-
NEWS: HealthLumen launches AlleleAtlas, a tool for estimating the prevalence of rare genetic diseases
HealthLumen has today announced the launch of AlleleAtlas, the genetic variant prevalence projection tool. The tool has been developed to bring a valuable resource to the rare disease community, including those engaged in rare disease research and therapeutics in the pharmaceutical, biotech and research spaces, and for patient advocacy organisations aiming to raise awareness.
-
World Diabetes Day 2024: A holistic approach to tackling diabetes
November 14th marks World Diabetes Day, a powerful opportunity to raise awareness of diabetes as a major global health issue. This year’s theme, “Breaking Barriers, Bridging Gaps”, calls for action to reduce diabetes risk factors and ensure equitable access to quality treatment worldwide [1]. The global diabetes crisis: A growing challenge Diabetes currently impacts over […]
-
HealthLumen modelling study for Nesta identifies the government interventions needed to halve obesity in the UK over five years
Study highlights which health policies are most likely to be effective in decreasing the prevalence of obesity, with fiscal policies expected to be particularly cost beneficial. This research has informed Nesta’s digital Blueprint tool – which provides data on the health, economic, and feasibility impacts of various obesity interventions – aligning with Nesta’s mission of halving obesity rates in the UK by 2030.
-
Join HealthLumen at key upcoming rare disease conferences in Q4 2024
HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.
-
NEWS: New research identifying the number of women at risk of FNAIT to be presented at ASHG 2024
Rallybio, a clinical-stage biotechnology company, will be presenting the findings of a genetic database analysis study conducted in partnership with HealthLumen on Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk across racially and ethnically diverse populations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The conference will take place from November 5–9 2024 in Denver, Colorado.
-
Genomics and precision medicine: The new frontier for microsimulation
“Genomics requires a form of modelling that can capture individual genetic differences and responses to therapy – a purpose to which microsimulation is eminently suited.”
This quote, from a seminal review paper by Professors Deborah Schofield and Rupendra Shrestha of Macquarie University, pioneers in applying microsimulation techniques for modelling the costs and benefits of genomic medicine, formed the basis for a fascinating recent discussion with the HealthLumen team, on the role of microsimulation modelling techniques in precision medicine.
-
Investing in prevention for men’s health: Increasing NHS Health Check attendance could save the NHS billions
HealthLumen was recently commissioned by Movember, one of the leading charities changing the face of men’s health, to quantify the economic impact of men’s poor health for their ‘Real Face of Men’s Health’ 2024 UK Report. The study found that in 2023 the five diseases that cause the largest number of years of life lost […]
-
NEWS: New genetic database analysis study reveals FNAIT risk across racially and ethnically diverse populations
HealthLumen has recently conducted a genetic database analysis study in partnership with Rallybio, a clinical-stage biotechnology company, focused on understanding the proportions of women at higher risk for Foetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) across a broad population of diverse ancestries. The results demonstrated that the proportion of women at higher risk for FNAIT was […]
-
Supporting rare disease patient advocacy with epidemiological insights
Awareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development. Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]
-
CKD epidemic: Global prevalence and economic burden set to surge by 2027 unless action is taken, Inside CKD studies reveal
In partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]